Veru Q3 Net Loss $7.0M; Enobosarm Trial Fully Enrolled; Patent Until 2044
Veru Inc. reported a Q3 fiscal 2026 net loss of $7.0 million, or $0.30 per share, an improvement from $7.3 million loss in Q3 2025. The company announced full enrollment of 239 patients in its Phase 2b PLATEAU clinical trial for enobosarm and semaglutide, with interim analysis results expected in Q1 2027. Additionally, Veru received a USPTO notice of allowance for a key U.S. patent for enobosarm and semaglutide, providing protection until at least October 2044. The company also secured a clinical supply agreement with Novo Nordisk for the PLATEAU trial.
Key Highlights
- Q3 2026 net loss was $7.0 million, or $0.30 per share, an improvement from Q3 2025.
- Phase 2b PLATEAU clinical trial fully enrolled with 239 patients, exceeding the 200-patient target.
- Interim analysis results for the PLATEAU trial are on track for calendar Q1 2027.
- Received USPTO notice of allowance for a key U.S. patent for enobosarm and semaglutide.
- Patent protection for enobosarm and semaglutide is expected until at least October 2044.
- Secured a clinical supply agreement with Novo Nordisk for the Phase 2b PLATEAU clinical trial.
- Cash, cash equivalents, and restricted cash totaled $23.9 million as of June 30, 2026.
Price Impact
More from VERU
Veru Inc. Advances Sabizabulin for Pancreatic Cancer; Discontinues Inflammation Program
VERU Reports Q3 Net Loss of $7.0M; Raises Going Concern Doubt
Veru Fully Enrolls PLATEAU Trial; Secures Enobosarm Patent to 2044